▲ +202.63% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $11.50, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 202.63% upside from the last price of $3.80.
The current consensus among 3 investment analysts is to buy stock in Synlogic. This Buy consensus rating has held steady for over two years.
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.